Active, not recruitingPhase 2NCT03836209
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PrECOG, LLC.
- Principal Investigator
- Selena Luger, MDUniversity of Pennsylvania
- Intervention
- Gilteritinib(drug)
- Enrollment
- 181 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2019 – 2026
Study locations (30)
- HonorHealth Research Institute, Scottsdale, Arizona, United States
- University of California, San Francisco-Fresno (University Oncology Associates), Clovis, California, United States
- UCLA, Los Angeles, California, United States
- Kaiser Permanente Oakland, Oakland, California, United States
- UC Irvine Health, Orange, California, United States
- Kaiser Permanente Roseville, Roseville, California, United States
- Kaiser Permanente Santa Clara, Santa Clara, California, United States
- Mayo Clinic- Jacksonville, FL, Jacksonville, Florida, United States
- Augusta University Medical Center, Augusta, Georgia, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Franciscan Health Indianapolis, Indianapolis, Indiana, United States
- University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Astellas Pharma Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03836209 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute